A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Trial details
- Registry ID
- NCT05442775
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775 | Cytokinetics | Phase 3 | Terminated | 2023-06-07Actual |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784 | Cytokinetics | Phase 3 | Terminated | 2023-07-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |